PT - JOURNAL ARTICLE AU - Daun, Julia T. AU - Capozzi, Lauren C. AU - Urgoiti, Gloria Roldan AU - McDonough, Meghan H. AU - Easaw, Jacob C. AU - McNeely, Margaret AU - Francis, George J. AU - Williamson, Tanya AU - Danyluk, Jessica AU - McLaughlin, Emma AU - Ospina, Paula A. AU - de Guzman Wilding, Marie AU - Radke, Lori AU - Driga, Amy AU - Lesiuk, Christine AU - Culos-Reed, S. Nicole TI - ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients – Study Protocol AID - 10.1101/2021.09.08.21263307 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.08.21263307 4099 - http://medrxiv.org/content/early/2021/09/10/2021.09.08.21263307.short 4100 - http://medrxiv.org/content/early/2021/09/10/2021.09.08.21263307.full AB - Background Patients with primary brain tumours lack access to exercise oncology and wellness resources. The purpose of the Alberta Cancer Exercise – Neuro-Oncology (ACE-Neuro) study is to assess the feasibility of a tailored neuro-oncology exercise program for patients across Alberta, Canada. The primary outcome is to assess the feasibility of ACE-Neuro. The secondary outcome is to examine preliminary effectiveness of ACE-Neuro on patient-reported outcomes and functional fitness.Methods Neuro-oncology patients with a malignant or benign primary brain tumour that are pre, on, or completed treatment, are >18 years, and able to consent in English are eligible to participate in the study. Following referral from the clinical team to cancer rehabilitation and the study team, participants are triaged to determine their appropriateness for ACE-Neuro or other cancer rehabilitation or physiatry resources. In ACE-Neuro, participants complete a tailored 12-week exercise program with pre-post assessments of patient-reported outcomes, functional fitness, and physical activity. ACE-Neuro includes individual and group-based exercise sessions, as well as health coaching.Conclusion We are supporting ACE-Neuro implementation into clinical cancer care, with assessment of needs enabling a tailored exercise prescription.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04831190Funding StatementThis work was supported by the Alberta Cancer Foundation. The first author is supported by an Alberta Innovates Health Solutions scholarship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Calgary Health Research Ethics Board of Alberta (HREBA) - Cancer Committee (CC) - HREBA.CC-20-0322.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data from this study are not available in a public archive. De-identified data from this study will be made available (as allowable according to institutional IRB standards) by emailing the corresponding author.